Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald F Watts

Showing results (681-690 of 706) with videos related to

Pageof 71
Sort By:
The Canadian Journal of Cardiology|August 11, 2018
Simplified Canadian Definition for Familial HypercholesterolemiaIsabelle Ruel, Diane Brisson, Sumayah Aljenedil, et al.
Journal of Lipid Research|April 11, 2025
Statin effects on the lipidome: Predicting statin usage and implications for cardiovascular risk predictionChangyu Yi, Kevin Huynh, Yvette Schooneveldt, et al.
European Heart Journal|August 29, 2022
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statementFlorian Kronenberg, Samia Mora, Erik S G Stroes, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
European Heart Journal|April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A Ference, Henry N Ginsberg, Ian Graham, et al.
Clinical Chemistry and Laboratory Medicine|December 20, 2019
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMMichel R Langlois, Børge G Nordestgaard, Anne Langsted, et al.
Atherosclerosis|January 14, 2020
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMBørge G Nordestgaard, Michel R Langlois, Anne Langsted, et al.
The Lancet. Diabetes & Endocrinology|June 2, 2016
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaul D Santos, Samuel S Gidding, Robert A Hegele, et al.
European Heart Journal|August 20, 2013
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis SocietyBørge G Nordestgaard, M John Chapman, Steve E Humphries, et al.
Atherosclerosis. Supplements|September 16, 2011
Familial hypercholesterolaemia: a model of care for AustralasiaGerald F Watts, David R Sullivan, Nicola Poplawski, et al.
Pageof 71

Showing results (681-690 of 706) with videos related to

Sort By:
Pageof 71
The Canadian Journal of Cardiology|August 11, 2018
Simplified Canadian Definition for Familial HypercholesterolemiaIsabelle Ruel, Diane Brisson, Sumayah Aljenedil, et al.
Journal of Lipid Research|April 11, 2025
Statin effects on the lipidome: Predicting statin usage and implications for cardiovascular risk predictionChangyu Yi, Kevin Huynh, Yvette Schooneveldt, et al.
European Heart Journal|August 29, 2022
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statementFlorian Kronenberg, Samia Mora, Erik S G Stroes, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2014
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and managementRobert A Hegele, Henry N Ginsberg, M John Chapman, et al.
European Heart Journal|April 27, 2017
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus PanelBrian A Ference, Henry N Ginsberg, Ian Graham, et al.
Clinical Chemistry and Laboratory Medicine|December 20, 2019
Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLMMichel R Langlois, Børge G Nordestgaard, Anne Langsted, et al.
Atherosclerosis|January 14, 2020
Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLMBørge G Nordestgaard, Michel R Langlois, Anne Langsted, et al.
The Lancet. Diabetes & Endocrinology|June 2, 2016
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia PanelRaul D Santos, Samuel S Gidding, Robert A Hegele, et al.
European Heart Journal|August 20, 2013
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis SocietyBørge G Nordestgaard, M John Chapman, Steve E Humphries, et al.
Atherosclerosis. Supplements|September 16, 2011
Familial hypercholesterolaemia: a model of care for AustralasiaGerald F Watts, David R Sullivan, Nicola Poplawski, et al.
Pageof 71